GPR35

Across TCGA pan-cancer cohorts, GPR35 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated GPR35 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher GPR35 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GPR35 expression acts as an unfavorable survival marker.

LUAD, CESC, and STAD are the cancer types where GPR35 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.053	0.751	<.001	42	view →
CESC	DFS	Median	II,III,IV	0.144	0.705	.004	18	view →
STAD	OS	Median	III,IV	0.001	0.630	<.001	18	view →
LGG	DFS	Median	All	0.110	0.833	<.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

GPR35–LUAD (OS)

Open the LUAD breakdown →